Qiu Baoshan, Cai Xueli, Zhou Lebo, Wang Xuan, Li Shan, Wang Nan, Jiang Lingling, Jing Jing, Wei Tiemin, Wang Yongjun, Pan Yuesong, Wang Yilong
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China. (B.Q., L.Z., X.W., N.W., L.J., J.J., Yongjun Wang, Y.P., Yilong Wang).
Chinese Institute for Brain Research, Beijing (B.Q., L.Z., N.W., Yilong Wang).
Arterioscler Thromb Vasc Biol. 2025 Jul 3. doi: 10.1161/ATVBAHA.125.322586.
The pathogenesis of atherosclerosis involves complex mechanisms, with inflammation playing a central role. Thromboinflammation may contribute to its development and progression. We investigated the association between circulating thromboinflammatory biomarkers and atherosclerotic plaques.
Participants aged 50 to 75 years from the baseline survey of the PRECISE study (Polyvascular Evaluation for Cognitive Impairment and Vascular Events) were included. Serum levels of thromboinflammatory biomarkers (sGPVI [soluble glycoprotein VI]; sADAMTS13 [soluble a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13]; and sP-selectin) were assessed by ELISA and Luminex assays and categorized into quartiles based on their empirical distribution within the study population. Eligible participants underwent imaging using computed tomography angiography and magnetic resonance imaging for coronary atherosclerosis, intracranial atherosclerosis, and extracranial atherosclerosis, respectively.
A total of 3019 participants (mean age, 61.20±6.68 years; 46.47% male) were analyzed. After multivariable adjustment, participants in the fourth quartile of sGPVI levels had higher odds of coronary atherosclerotic plaque burden (common odds ratio, 1.42 [95% CI, 1.14-1.76]; =0.0017). Conversely, those in the highest sADAMTS13 quartile had lower odds of coronary plaques (odds ratio, 0.75 [95% CI, 0.60-0.93]; =0.0094), as well as reduced coronary plaque burden, including segment involvement score (common odds ratio, 0.75 [95% CI, 0.61-0.93]; =0.0087) and segment stenosis score (common odds ratio, 0.75 [95% CI, 0.61-0.93]; =0.0086). No significant associations were observed between sGPVI or sADAMTS13 levels and intracranial or extracranial atherosclerosis. Likewise, after multivariable adjustment, no significant associations were observed between sP-selectin levels and coronary, intracranial, or extracranial atherosclerosis.
In our study, serum sADAMTS13 levels showed a negative association with both the presence and burden of coronary atherosclerosis, while sGPVI levels showed a positive association with the burden of coronary atherosclerosis. However, significant associations between the level of thromboinflammatory biomarkers, intracranial atherosclerosis, and extracranial atherosclerosis were not found.
动脉粥样硬化的发病机制涉及复杂的机制，炎症起着核心作用。血栓炎症可能促进其发展和进展。我们研究了循环血栓炎症生物标志物与动脉粥样硬化斑块之间的关联。
纳入了来自PRECISE研究（认知障碍和血管事件的多血管评估）基线调查的50至75岁参与者。通过酶联免疫吸附测定（ELISA）和Luminex测定法评估血栓炎症生物标志物（可溶性糖蛋白VI[sGPVI]；可溶性含血小板反应蛋白基序的解聚素和金属蛋白酶13[sADAMTS13]；以及可溶性P选择素）的血清水平，并根据它们在研究人群中的经验分布分为四分位数。符合条件的参与者分别接受计算机断层血管造影和磁共振成像，以评估冠状动脉粥样硬化、颅内动脉粥样硬化和颅外动脉粥样硬化。
共分析了3019名参与者（平均年龄61.20±6.68岁；46.47%为男性）。经过多变量调整后，sGPVI水平处于第四四分位数的参与者发生冠状动脉粥样硬化斑块负荷的几率更高（共同优势比，1.42[95%置信区间，1.14-1.76]；P=0.0017）。相反，sADAMTS13四分位数最高的参与者发生冠状动脉斑块的几率较低（优势比，0.75[95%置信区间，0.60-0.93]；P=0.0094），冠状动脉斑块负荷也较低，包括节段累及评分（共同优势比，0.75[95%置信区间，0.61-0.93]；P=0.0087）和节段狭窄评分（共同优势比，0.75[95%置信区间，0.61-0.93]；P=0.0086）。未观察到sGPVI或sADAMTS13水平与颅内或颅外动脉粥样硬化之间存在显著关联。同样，经过多变量调整后，未观察到可溶性P选择素水平与冠状动脉、颅内或颅外动脉粥样硬化之间存在显著关联。
在我们的研究中，血清sADAMTS13水平与冠状动脉粥样硬化的存在和负荷均呈负相关，而sGPVI水平与冠状动脉粥样硬化的负荷呈正相关。然而，未发现血栓炎症生物标志物水平与颅内动脉粥样硬化和颅外动脉粥样硬化之间存在显著关联。
